Acquired MiR-142 Deficit in Leukemic Stem Cells Suffices to Drive Chronic Myeloid Leukemia into Blast Crisis
Overview
Authors
Affiliations
The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of miR-142 in CD34CD38 blasts from BC CML patients than in those from CP CML patients, suggesting that miR-142 deficit is implicated in BC evolution. Thus, we create miR-142 knockout CML (i.e., miR-142BCR-ABL) mice, which develop BC and die sooner than miR-142 wt CML (i.e., miR-142BCR-ABL) mice, which instead remain in CP CML. Leukemic stem cells (LSCs) from miR-142BCR-ABL mice recapitulate the BC phenotype in congenic recipients, supporting LSC transformation by miR-142 deficit. State-transition and mutual information analyses of "bulk" and single cell RNA-seq data, metabolomic profiling and functional metabolic assays identify enhanced fatty acid β-oxidation, oxidative phosphorylation and mitochondrial fusion in LSCs as key steps in miR-142-driven BC evolution. A synthetic CpG-miR-142 mimic oligodeoxynucleotide rescues the BC phenotype in miR-142BCR-ABL mice and patient-derived xenografts.
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.
Chen F, Zhao D, Xu Y, Zhang Y, Chen M, Pathak K Nat Commun. 2025; 16(1):1253.
PMID: 39893171 PMC: 11787332. DOI: 10.1038/s41467-025-56383-y.
PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.
Zhou M, Huang Y, Xu P, Li S, Duan C, Lin X Adv Sci (Weinh). 2024; 12(5):e2308586.
PMID: 39668478 PMC: 11791931. DOI: 10.1002/advs.202308586.
Zeng C, Nie D, Wang X, Zhong S, Zeng X, Liu X Mol Cancer. 2024; 23(1):240.
PMID: 39465372 PMC: 11514791. DOI: 10.1186/s12943-024-02162-0.
Absar M, Alanazi N, Siyal A, Shammas M, Mahmood A, Basit S J Popul Ther Clin Pharmacol. 2024; 29(2):311-320.
PMID: 38465242 PMC: 10923263. DOI: 10.53555/jptcp.v29i02.4161.
Goldberg L, Haas E, Urak R, Vyas V, Pathak K, Garcia-Mansfield K Cancer Res. 2024; 84(7):1048-1064.
PMID: 38315779 PMC: 10984768. DOI: 10.1158/0008-5472.CAN-23-2299.